Comparison
Cagrilintide vs. Exenatide
Two peptides side-by-side — identity, evidence base, legal status and known adverse events.
Identity
Category
Metabolic
Metabolic
CAS no.
1415456-99-3
141758-74-9
Molecular weight
4253.7 g/mol
4186.6 g/mol
Half-life
168 h
2.4 h
Sequence
KCNTATCATQRLANFLVRSSNNLGPVLPPTNVGSNTYHGEGTFTSDLSKQMEEEAVRLFIEWLKNGGPSSGAPPPSMechanism of action
Cagrilintide
Cagrilintide binds amylin receptors (AMY1, AMY3, formed by the calcitonin receptor plus RAMP proteins). Activation delays gastric emptying, inhibits postprandial glucagon secretion and modulates central satiety signalling via area postrema neurons. An acyl modification enables albumin binding and thereby weekly dosing.
Exenatide
Exenatide is a 39-amino-acid peptide with about 53% sequence homology to human GLP-1. A glycine substitution at position 2 prevents dipeptidyl-peptidase-IV cleavage and extends the half-life from native GLP-1 (minutes) to about 2.4 hours. GLP-1 receptor activation glucose-dependently stimulates insulin secretion, inhibits glucagon and delays gastric emptying.
Evidence base
Highest evidence
Human RCT
Human RCT
Studies
4
5
of which in humans
3
4
Effects recorded
3
3
Open conflicts
0
1
Documented adverse events
1
2